Open Access. Powered by Scholars. Published by Universities.®
Analytical, Diagnostic and Therapeutic Techniques and Equipment
- Keyword
-
- Acute Kidney Injury (1)
- Acute kidney injury (1)
- Adult (1)
- Aged (1)
- Aged, 80 and over (1)
-
- Anti-Bacterial Agents (1)
- Beta-Lactamase Inhibitors (1)
- Cephalosporins (1)
- Clinical therapeutics (1)
- Drug Therapy, Combination (1)
- Extended infusion (1)
- Female (1)
- Humans (1)
- Kidney (1)
- Male (1)
- Middle Aged (1)
- Multidrug resistance (1)
- Penicillanic Acid (1)
- Pharmacokinetics (1)
- Pharmacology (1)
- Piperacillin (1)
- Retrospective Studies (1)
- Thienamycins (1)
- Toxicity (1)
- Β-lactams (1)
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Influence Of Β-Lactam Infusion Strategy On Acute Kidney Injury, Sarah E. Cotner, Wilbur Cliff Rutter, Donna R. Burgess, Katie L. Wallace, Craig A. Martin, David S. Burgess
Influence Of Β-Lactam Infusion Strategy On Acute Kidney Injury, Sarah E. Cotner, Wilbur Cliff Rutter, Donna R. Burgess, Katie L. Wallace, Craig A. Martin, David S. Burgess
Pharmacy Practice and Science Faculty Publications
Limited literature is available assessing nephrotoxicity with prolonged β-lactam infusions. This study compared the incidence of acute kidney injury (AKI) associated with a prolonged β-lactam infusion or an intermittent infusion. This was a retrospective, matched-cohort study at an academic medical center from July 2006 to September 2015. Adult patients who received piperacillin-tazobactam (TZP), cefepime (FEP), or meropenem (MEM) for at least 48 h were evaluated. Patients were excluded for preexisting renal dysfunction or pregnancy. The primary outcome was difference in incidence of AKI evaluated using the RIFLE (risk, injury, failure, loss, and end-stage) criteria. Patients in the intermittent group …
Nephrotoxicity In Patients With Or Without Cystic Fibrosis Treated With Polymyxin B Compared To Colistin, Ryan L. Crass, Wilbur Cliff Rutter, Donna R. Burgess, Craig A. Martin, David S. Burgess
Nephrotoxicity In Patients With Or Without Cystic Fibrosis Treated With Polymyxin B Compared To Colistin, Ryan L. Crass, Wilbur Cliff Rutter, Donna R. Burgess, Craig A. Martin, David S. Burgess
Pharmacy Practice and Science Faculty Publications
Nephrotoxicity is the primary adverse effect of the polymyxins. The relative rates of toxicity of polymyxin B and colistin have not been fully elucidated, especially in patients with cystic fibrosis (CF). A retrospective cohort study of adults treated with polymyxin B or colistin for at least 48 h was conducted. The primary endpoint was the incidence of kidney injury assessed by RIFLE (i.e., risk, injury, failure, loss, end-stage renal disease) criteria. Risk factors for kidney injury were evaluated using multivariate Cox regression. A total of 414 patients were evaluated, 220 of whom had CF. In patients without CF, there was …